What is FLNA's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near n/a (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for FLNA?

P/E (TTM) is n/a and 52-week range is $0.62 to $2.27 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s FLNA figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for FLNA?

The company profile lists net income (TTM) near -$42M, EPS (TTM) near -$0.88 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Filana Therapeutics, Inc. based, and what identifiers does Chartloom list?

The company context section lists headquarters in Austin, Texas, US, 48.3M shares outstanding, ISIN US14817C1071 when available from company profile and filing metadata.

Please enable JavaScript to continue using this application.

Filana Therapeutics, Inc.

$FLNA

Health Care · Pharmaceuticals

IR Run Scenarios

Overview Charts AI Summary Financials Valuation

Profile

Read AI summary

Filana Therapeutics, Inc. engages in the development of novel drugs and diagnostics. The company is headquartered in Austin, Texas and currently employs 17 full-time employees. The company went IPO on 2000-07-14. The firm's science is based on stabilizing, but not removing, a critical protein in the brain for patients with disorders such as Alzheimer’s disease or TSC. The company has two biopharmaceutical assets under development: Simufilam and SavaDx. Simufilam, its lead therapeutic product candidate, is an oral treatment for Alzheimer’s disease and TSC-related epilepsy. Simufilam targets an altered form of a protein called filamin A (FLNA) in the brain of patients with disorders such as Alzheimer’s disease or TSC. SavaDx, its lead investigational diagnostic product candidate, is an early-stage program focused on detecting the presence of Alzheimer’s disease from a small sample of blood.

Employees

Website

www.filanatx.com

IPO

2000-07-14

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)

Net income (TTM)

EPS (TTM)

P/E (price / listing EPS)

P/S (TTM)

Forward P/E

Forward P/S

EV / EBITDA

PEG (TTM)

FCF yield (TTM)

Gross margin (TTM)

Net margin (TTM)

Forward revenue growth (NTM)

Dividend / share (TTM)

Dividend yield (TTM)

Payout ratio (TTM)

Dividend growth (5Y)

Company context

Exchange

NASDAQ NMS - GLOBAL MARKET

ISIN

US14817C1071

Headquarters

Austin, Texas, US

Shares outstanding

48.3M

NAICS sector

Professional, Scientific, and Technical Services

Institutional ownership

26.73%

Browse other companiesFree AI scores and summaries for more stocks

Filana Therapeutics, Inc. (FLNA) Stock Analysis & Quote